Tag Archives: CRTX

Healthcare Sector Highlight: Allscripts Healthcare (NASDAQ:MDRX), Cornerstone Therapeutics (NASDAQ:CRTX) – MDRX, CRTX, PFE, PWER, SPWR, ELNK

Posted on February 20, 2013 by Thomas Vedder

Investors reacted positively to the technology stocks on Thursday. Key movement were observed in Power One Inc (NASDAQ:PWER) and SunPower Corporation (NASDAQ:SPWR) on percentage gainers side while EarthLink, Inc (NASDAQ:ELNK) was major percentage decliners.

Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) swung …

Posted in Healthcare, Latest Headlines | Tagged Allscripts Healthcare, Cornerstone Therapeutics, CRTX, EarthLink, ELNK, MDRX, NASDAQ:CRTX, NASDAQ:ELNK, NASDAQ:MDRX, NASDAQ:PWER, NASDAQ:SPWR, NYSE:PFE, PFE, Pfizer, Power One, PWER, SPWR, SunPower | Comments Off

Healthcare Sector Soars on Thursday; Johnson & Johnson (NYSE:JNJ) Picks Bayer Chief for Consumer Unit while Gentium (NASDAQ:GENT) Reports Second Quarter Results – JNJ, GENT, VPHM, CUR, RGDX, CRTX

Posted on September 14, 2012 by Geoff Noir

Healthcare sector responded positively on Thursday’s trading session and sector surged +1.00%. If we look at the top movers of the sector so Neuralstem, Inc. (NYSEAMEX:CUR) and Response Genetics, Inc. (NASDAQ:RGDX) were major percentage gainers while major percentage Loser was …

Posted in Healthcare, Latest Headlines | Tagged Cornerstone Therapeutics, CRTX, CUR, GENT, Gentium S.p.A, JNJ, Johnson, NASDAQ:CRTX, NASDAQ:GENT, NASDAQ:RGDX, NASDAQ:VPHM, Neuralstem, NYSE:JNJ, NYSEAMEX:CUR, Response Genetics, RGDX, Viropharma, VPHM | Comments Off

Forest Laboratories (NYSE:FRX) Needs Deal to Oppose 80% Decline in Profit – FRX, GSK, CRTX, MYL

Posted on July 6, 2012 by Thomas Vedder

The New York-based Forest Laboratories, Inc (NYSE:FRX) requires purchases to counter an anticipated 80% decline in profit current year as patents on its top-selling drugs start to end.

Almost 3 quarters of the corporation’s over $4.5 billion of sales previous …

Posted in Healthcare, Latest Headlines | Tagged Cornerstone, CRTX, Forest Laboratories, FRX, GlaxoSmithKline, GSK, MYL, Mylan, NASDAQ:CRTX, NASDAQ:MYL, NYSE:FRX, NYSE:GSK | Comments Off

Forest Laboratories (NYSE:FRX) Sues By Second Biggest Investor on Company’s Record Access Issue – FRX, GSK, CRTX, MYL

Posted on July 2, 2012 by Geoff Noir

Carl Icahn took legal action against Forest Laboratories, Inc (NYSE:FRX) for access to its books and records, charging that the company is withholding information from shareholders and has not met its remarks on corporate governance.

According to the complaint made …

Posted in Healthcare, Latest Headlines | Tagged Cornerstone, CRTX, Forest Laboratories, FRX, GlaxoSmithKline, GSK, MYL, Mylan, NASDAQ:CRTX, NASDAQ:MYL, NYSE:FRX, NYSE:GSK | Comments Off

What the Fuss FiberTower, BioLine and Cornerstone Therapeutics?

Posted on September 13, 2011 by Martin Timble

U.S. markets are struggling for direction so far this Tuesday, swinging from small declines to small gains. Investors are trying to make out exactly what is going on with the U.S. economy and the uncertainty surrounding the debt crisis in …

Posted in Main Post | Tagged Berkshire Hathaway, BioLine, BioLine RX, BLRX, CEO, clinical data, company, Cornerstone Therapeutics, CRTX, CUROSURF, debt crisis, drug, economy, Europe, FiberTower, findings, FTWR, gains, Holdings, investment portfolio, investors, Kinneret Savitsky, markets, NASDAQ, NASDAQ:BLRX, NASDAQ:CRTX, NASDAQ:FTWR, Peninsula Capital Advisors, Phase 1 trial, portfolio, RDS, respiratory distress syndrome, stock, study, Survanta, Ted Weschler, trades, trading, treatment, Warren Buffet, wireless communications | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.